Index RUT
P/E -
EPS (ttm) -1.14
Insider Own 24.87%
Shs Outstand 120.71M
Perf Week -3.27%
Market Cap 253.29M
Forward P/E -
EPS next Y -0.72
Insider Trans -0.21%
Shs Float 91.93M
Perf Month -19.46%
Income -134.81M
PEG -
EPS next Q -0.17
Inst Own 74.74%
Short Float 12.03%
Perf Quarter -58.93%
Sales 38.30M
P/S 6.61
EPS this Y 58.18%
Inst Trans 4.06%
Short Ratio 5.98
Perf Half Y 0.98%
Book/sh 0.23
P/B 9.05
EPS next Y -16.36%
ROA -54.52%
Short Interest 11.06M
Perf Year -78.32%
Cash/sh 1.50
P/C 1.38
EPS next 5Y -
ROE -292.19%
52W Range 0.80 - 9.60
Perf YTD -10.78%
Dividend Est. -
P/FCF -
EPS past 5Y 11.93%
ROI -257.73%
52W High -78.44%
Beta 1.54
Dividend TTM -
Quick Ratio 3.51
Sales past 5Y 12371.94%
Gross Margin 95.77%
52W Low 158.30%
ATR (14) 0.19
Dividend Ex-Date -
Current Ratio 3.51
EPS Y/Y TTM 46.52%
Oper. Margin -350.30%
RSI (14) 31.38
Volatility 6.20% 7.13%
Employees 123
Debt/Eq 1.18
Sales Y/Y TTM 18.40%
Profit Margin -352.01%
Recom 1.44
Target Price 6.38
Option/Short Yes / Yes
LT Debt/Eq 0.87
EPS Q/Q 69.56%
Payout -
Rel Volume 0.69
Prev Close 2.22
Sales Surprise 8.73%
EPS Surprise 10.31%
Sales Q/Q 18.50%
Earnings May 09 BMO
Avg Volume 1.85M
Price 2.07
SMA20 -13.37%
SMA50 -30.27%
SMA200 -22.61%
Trades
Volume 1,274,537
Change -6.76%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-19-24 Upgrade
JP Morgan
Underweight → Neutral
$5
Feb-29-24 Upgrade
Wedbush
Neutral → Outperform
$2 → $7
Feb-29-24 Upgrade
Guggenheim
Neutral → Buy
$7
Feb-29-24 Upgrade
BTIG Research
Neutral → Buy
$6
Dec-04-23 Upgrade
Citigroup
Neutral → Buy
$1 → $5
Jul-28-23 Downgrade
Robert W. Baird
Outperform → Neutral
$7 → $1
Jul-27-23 Downgrade
Wedbush
Outperform → Neutral
Jul-27-23 Downgrade
Truist
Buy → Hold
Jul-27-23 Downgrade
JP Morgan
Neutral → Underweight
Jul-27-23 Downgrade
Guggenheim
Buy → Neutral
Jul-27-23 Downgrade
Citigroup
Buy → Neutral
Jul-27-23 Downgrade
BTIG Research
Buy → Neutral
Jun-16-23 Downgrade
JP Morgan
Overweight → Neutral
$11 → $5
Jun-15-23 Initiated
Guggenheim
Buy
$14
Mar-16-23 Upgrade
JP Morgan
Neutral → Overweight
$10
Jan-20-23 Initiated
Citigroup
Buy
$12
Nov-21-22 Initiated
Truist
Buy
$12
Oct-15-21 Resumed
BTIG Research
Buy
$32
Aug-30-21 Initiated
H.C. Wainwright
Buy
$28
Mar-31-21 Initiated
Credit Suisse
Neutral
$18
Show Previous Ratings
May-22-24 08:00AM
May-10-24 04:36PM
03:15PM
May-09-24 11:55AM
08:05AM
06:59AM
Loading…
06:59AM
May-03-24 04:30PM
May-02-24 08:00AM
Apr-04-24 04:30PM
Feb-29-24 08:41AM
Feb-28-24 09:49PM
(Thomson Reuters StreetEvents) +13.58%
08:10AM
07:35AM
07:00AM
Feb-27-24 08:01AM
08:00AM
Loading…
Feb-21-24 08:00AM
Feb-20-24 10:00AM
Feb-01-24 08:00AM
Jan-05-24 08:01AM
Dec-01-23 04:30PM
Nov-08-23 02:42PM
12:13AM
(Thomson Reuters StreetEvents)
Nov-07-23 08:10AM
07:00AM
Oct-31-23 04:30PM
08:00AM
Sep-07-23 06:30AM
(American City Business Journals)
Sep-06-23 07:00AM
Aug-18-23 09:35AM
Aug-16-23 09:35AM
09:40AM
Loading…
Aug-08-23 09:40AM
08:00AM
Aug-04-23 04:05PM
Jul-28-23 10:13AM
03:14AM
Jul-27-23 09:34PM
01:44PM
(American City Business Journals)
07:06AM
Jul-13-23 09:45AM
Jul-06-23 04:05PM
Jun-22-23 11:04AM
Jun-16-23 10:43AM
02:26AM
Jun-15-23 09:32AM
07:36AM
07:30AM
Jun-13-23 06:00AM
Jun-02-23 04:05PM
May-28-23 09:06AM
May-24-23 08:00AM
May-09-23 08:35AM
07:00AM
May-04-23 04:05PM
May-03-23 08:00AM
May-02-23 08:00AM
Apr-26-23 04:05PM
Apr-19-23 02:42PM
Apr-17-23 11:07AM
Apr-06-23 04:05PM
Apr-05-23 02:00PM
Mar-16-23 11:20AM
Mar-13-23 02:00PM
07:54AM
07:30AM
Mar-10-23 07:10PM
Mar-03-23 04:05PM
Mar-02-23 08:55PM
Mar-01-23 05:24AM
Feb-28-23 11:51PM
(Thomson Reuters StreetEvents) +11.60%
07:00AM
Feb-21-23 08:00AM
Feb-03-23 04:05PM
Feb-02-23 08:00AM
Feb-01-23 08:00AM
Jan-25-23 08:00AM
Jan-20-23 03:16PM
Jan-16-23 02:18AM
Jan-06-23 04:05PM
07:00AM
Dec-31-22 07:42AM
Dec-23-22 12:46PM
(American City Business Journals)
10:08AM
Dec-22-22 04:08PM
04:05PM
Dec-14-22 08:00AM
Dec-02-22 04:05PM
Nov-08-22 08:00AM
Nov-07-22 08:25AM
07:00AM
Nov-04-22 04:05PM
Oct-31-22 08:00AM
Oct-30-22 10:13AM
Oct-17-22 09:40AM
Oct-06-22 04:05PM
Oct-04-22 04:05PM
Sep-30-22 08:02AM
Sep-12-22 08:00AM
Sep-06-22 08:00AM
Sep-02-22 04:05PM
Sep-01-22 10:17AM
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Protopapas Anna Director Jan 16 '24 Sale 2.71 29,399 79,671 125,153 Jan 17 05:21 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 16 '24 Sale 2.71 10,409 28,208 199,329 Jan 17 05:19 PM DeSchuytner Brian SVP, COO & CFO Jan 16 '24 Sale 2.71 9,327 25,276 54,511 Jan 17 05:18 PM Mandelia Ashish VP, Chief Accounting Officer Jan 16 '24 Sale 2.71 5,025 13,618 23,328 Jan 17 05:20 PM Carvajal Alejandra SVP, Chief Legal Officer Jan 16 '24 Sale 2.71 4,381 11,873 27,403 Jan 17 05:18 PM Bala Mohan SVP, Chief Development Officer Jan 16 '24 Sale 2.71 3,431 9,298 14,052 Jan 17 05:16 PM MISRA TUSHAR SVP, Chief Manuf. Officer Jan 16 '24 Sale 2.71 3,357 9,097 17,966 Jan 17 05:21 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 15 '24 Option Exercise 0.00 15,208 0 209,738 Jan 17 05:19 PM DeSchuytner Brian SVP, COO & CFO Jan 15 '24 Option Exercise 0.00 10,208 0 63,838 Jan 17 05:18 PM Protopapas Anna Director Jan 15 '24 Option Exercise 0.00 38,958 0 154,552 Jan 17 05:21 PM Mandelia Ashish VP, Chief Accounting Officer Jan 15 '24 Option Exercise 0.00 5,352 0 28,353 Jan 17 05:20 PM Mandelia Ashish VP, Chief Accounting Officer Jan 14 '24 Option Exercise 0.00 4,783 0 23,001 Jan 17 05:20 PM MISRA TUSHAR SVP, Chief Manuf. Officer Jan 14 '24 Option Exercise 0.00 1,458 0 21,323 Jan 17 05:21 PM Protopapas Anna Director Jan 14 '24 Option Exercise 0.00 16,750 0 115,594 Jan 17 05:21 PM Carvajal Alejandra SVP, Chief Legal Officer Jan 14 '24 Option Exercise 0.00 2,500 0 31,784 Jan 17 05:18 PM DeSchuytner Brian SVP, COO & CFO Jan 14 '24 Option Exercise 0.00 6,250 0 55,630 Jan 17 05:18 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 14 '24 Option Exercise 0.00 4,792 0 194,530 Jan 17 05:19 PM Lowinger Timothy B SVP, Chief Sci.&Tech. Officer Jan 13 '24 Option Exercise 0.00 9,375 0 189,738 Jan 17 05:19 PM DeSchuytner Brian SVP, COO & CFO Jan 13 '24 Option Exercise 0.00 10,000 0 47,380 Jan 17 05:18 PM Carvajal Alejandra SVP, Chief Legal Officer Jan 13 '24 Option Exercise 0.00 8,958 0 29,284 Jan 17 05:18 PM Bala Mohan SVP, Chief Development Officer Jan 13 '24 Option Exercise 0.00 8,750 0 17,483 Jan 17 05:16 PM Protopapas Anna Director Jan 13 '24 Option Exercise 0.00 31,250 0 98,844 Jan 17 05:21 PM MISRA TUSHAR SVP, Chief Manuf. Officer Jan 13 '24 Option Exercise 0.00 7,083 0 19,865 Jan 17 05:21 PM Mandelia Ashish VP, Chief Accounting Officer Jan 13 '24 Option Exercise 0.00 2,645 0 18,218 Jan 17 05:20 PM Bala Mohan SVP, Chief Development Officer Oct 26 '23 Sale 1.13 1,912 2,161 8,733 Oct 27 04:07 PM Bala Mohan SVP, Chief Development Officer Oct 25 '23 Option Exercise 0.00 6,250 0 10,645 Oct 27 04:07 PM MISRA TUSHAR SVP, Chief Manuf. Officer Aug 17 '23 Sale 1.18 1,908 2,251 11,507 Aug 18 04:01 PM MISRA TUSHAR SVP, Chief Manuf. Officer Aug 16 '23 Option Exercise 0.00 6,250 0 13,415 Aug 18 04:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite